An investigational drug candidate in development for schizophrenia.

Alkermes reports data from aripiprazole lauroxil stage 3 clinical trial for treatment of schizophrenia Alkermes plc today announced the presentation of data from its stage 3 clinical trial of aripiprazole lauroxil, an investigational drug candidate in development for schizophrenia, in the American Culture of Clinical Psychopharmacology Annual Conference in Hollywood, Fla. In the pivotal research, both doses of aripiprazole lauroxil examined, 441 mg and 882 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in Negative and positive Syndrome Scale ratings, met all secondary endpoints and demonstrated significant improvements in schizophrenia symptoms versus placebo.

On the other hand, gefitinib and erlotinib have already been been shown to be effective seeing that monotherapy in these individuals. ‘Studies using novel biomarker-based methods may guide the selection of individualized targeted therapies,’ write colleagues and Paz-Ares. Certified from medwireNews with authorization from Springer Healthcare Ltd. All privileges reserved. Neither of the parties endorse or suggest any commercial products, services, or equipment.. Adverse birth outcomes explain epilepsy mortality A higher rate of mortality is known to be associated with epilepsy, but the precise contribution of the underlying wellness factors is unknown. The results from the study of a large cohort of individuals born in Denmark in 1977 through 2006 were reported today at the American Epilepsy Society meeting here.On the other hand, gefitinib and erlotinib have already been been shown to be effective seeing that monotherapy in these individuals. ‘Studies using novel biomarker-based methods may guide the selection of individualized targeted therapies,’ write colleagues and Paz-Ares. Certified from medwireNews with authorization from Springer Healthcare Ltd. All privileges reserved. Neither of the parties endorse or suggest any commercial products, services, or equipment.. Adverse birth outcomes explain epilepsy mortality A higher rate of mortality is known to be associated with epilepsy, but the precise contribution of the underlying wellness factors is unknown. The results from the study of a large cohort of individuals born in Denmark in 1977 through 2006 were reported today at the American Epilepsy Society meeting here.